Introduction
The similarities between simian immunodeficiency viruses (SIVs) and human immunodeficiency viruses (HIVs) both in genomic organization and in the disease that they may cause in their respective hosts has enabled the SIV infection of macaques to be used as a model for HIV vaccine development (for a review see Desrosiers & Letvin, 1987) . The external glycoproteins of these viruses are primary candidates for vaccine components as they are involved in virus attachment to host cells and are expressed on the surface of virus-infected cells; thus systematic comparisons of immune responses to the respective external glycoproteins are needed to assist in the rational design of HIV-1 vaccines using the SIV model.
HIV-l-infected patients make neutralizing antibody responses with a predominant reactivity to the third hypervariable loop domain (V3) of the external glycoprotein. Recently, it was shown that chimpanzees may be protected from HIV-1 challenge by passive administration of a monoclonal antibody with specificity for the HIV-1 V3 domain (Emini et al., 1992) . Furthermore a number of chimpanzees have been protected by immunization with recombinant envelope preparations (Berman et al. 1990 ) and protection may correlate with the level of neutralizing antibody present at the time of challenge. Antibodies to the external glycoprotein may also mediate other biological effects such as antibodydependent cell-mediated cytotoxicity (Tyler et al., 1989) and complement-mediated virolysis (Spear et al., 1990) .
Similarly, in SIV experiments, it is evident that the virus envelope may be protective. Combined vaccination with vaccinia virus expressing SIV glycoprotein gpl60 followed by immunization with partially purified recombinant gpl60 produced from baculovirus has protected macaques against challenge with a biological clone of SIV .... (Hu et al., 1992) . In addition, peptides made from conserved regions of SIV envelope have been shown to modify the outcome of infection with SIVmne (Shafferman et al., 1991) . Studies with SIV .... have been less promising; however this may be due, at least in part, to inappropriate virus challenge and selective or poor 0001-1491 © 1993 SGM antigenicity of the recombinant envelope preparations used.
Recent studies with monoclonal antibodies have identified a number of B cell epitopes on the SIVma e external envelope and neutralizing activity has been associated with both linear and conformationally determined epitopes Benichou et al., 1992) . This report describes antibody responses to the SIVma e external glycoprotein measured in rhesus macaques infected with either the uncloned SIVma c 32H isolate or the J5 molecular clone of SIVma c 32H (Rud et al., 1992) and in animals vaccinated with formalin-inactivated SIV .... 32H using alum or syntex adjuvant formulation (saf-1) adjuvants. Reactivity to a non-continuous virus neutralization epitope was measured by competitive binding assay using a monoclonal antibody with specificity for the SIVma e envelope (Kent et al., 1991 . The response to linear antigenic determinants of the SIV .... external glycoprotein was measured by binding to a series of 20-mer overlapping peptides.
Methods
SIVma~-infected macaque sera. Sera were taken from rhesus macaques each infected, as part of a titration experiment, with a single dilution of uncloned SIVm~ c 32H or the infectious molecular clone derived from SIV ..... 32H (pJ5). All seropositive animals had been confirmed as infected by the regular isolation of virus from peripheral blood mononuclear cells (PBMCs) and by the detection ofproviral SIV DNA using PCR. Seven of eight animals infected with uncloned virus had pathology consistent with AIDS at the time of death, between 120 and 780 days post-infection . One animal in this group and all animals infected with the J5 molecular clone remained well apart from transient lymphadenopathy over the period of the study (greater than 870 days and 250 days, respectively).
SIV, n,c-vaccinated macaque sera. Sera were taken on the day of virus challenge from animals vaccinated with formalin-inactivated partially purified SIVm~ o 32H. Details of the vaccine preparation have been described previously (Cranage et al., , 1993 . Virus was purified from the cell-free supernatant of the human T cell line C8166 infected with SIVm~ 0 32H. Virus-infected cells were grown in static culture and fed twice weekly with uninfected cells in RPMI 1640 with 10 % fetal calf serum (growth medium) in a ratio of 1 to 4 (v/v). Virus was harvested at between 10 and 14 passages from inoculation of cells with seed stock, when the cells had an approximate density of 5 x 10 r cells/l. Infected cells were removed by low-speed centrifugation and the virus was removed from the supernatant by centrifugation at 88 000 g. Virus pellets were resuspended in TNE buffer pH 7.5 (20 mM-Tris-HC1, 0.1 M-NaC1, 1 mM-EDTA) and allowed to disaggregate by overnight incubation on ice. Virus was partially purified by gel filtration chromatography on Sepharose 4B. The first two fractions after the void volume, containing approximately 16 % of the total protein applied to the column and approximately 86% of the total eluted reverse transcriptase (RT) activity, were pooled from each column run, and the virus was recovered by centrifugation at 200000 g for 45 rain. Pellets were resuspended in PBS pH 7.2, and the protein concentration was adjusted to 2.5 mg/ml before treatment with 0.8 % formaldehyde for 24 h at 4 °C. Vaccine samples were stored at -70 °C before use. The animals were immunized intramuscularly with vaccine formulated in saf-1 containing threonyl muramyl dipeptide in a pleuronic L121 plus squalene vehicle and a further six animals received vaccine formulated 
*Region refers to the HIV-1 equivalent (Almond et al., 1992) .
Peptide 35 contains the variable region described by Burns & Desrosiers (1991) .
in alum (aluminium hydroxide; Alhydrogel, Superfos Biosector) ( Table  1) . Animals in groups receiving vaccine given in alum were part of an E.C. Concerted Action experiment on adjuvant comparisons. All vaccinated animals were protected from intravenous challenge with 10 median monkey infectious doses of either homologous (SIV~e 32H) or heterologous (SIVsmB670) virus grown on human cells as reported previously .
The rhesus macaques used in this study were all colony-bred within the U.K. and were housed according to the Home Office code of practice for the housing and care of animals used in scientific procedures (1989) . Primates were anaesthetized with ketamine hydrochloride for all procedures requiring their removal from cages.
Competitive ELISA. Monoclonal antibody KK17 was purified from ascitic fluid by chromatography on Protein @Sepharose. Purified immunoglobulin was labelled using biotinamidocaproyl hydrazide and stored at 4 °C before use. An NP40 lysate of SIV-infected C8166 cells was dried onto Falcon 3912 Micro Test III PVC assay plates at 500 ng/ml by overnight incubation at 37 °C. Plates were blocked by incubation with 50 lal/well PBS containing 0.5 % (v/v) Tween 20 (PBST) and 10 % (v/v) fetal calf serum (blocking buffer A) for 90 min. The plates were washed five times with PBST and each well was incubated for 90 min with 50 gl of a solution consisting of biotinylated monoclonal antibody KK17 (Kent et al., 1991) and a 1/200 dilution of monkey serum in blocking buffer A. In initial experiments, serial dilutions of monkey sera were mixed with labelled KK17 and endpoint titres were determined. There was a linear relationship between the endpoint, determined by titration, and the percentage specific inhibition determined when a serum concentration of 1/200 was used and therefore this dilution was used subsequently. Plates were washed as before and incubated for 30 min with a 1 : 5000 dilution (50 gl/well) of streptavidin horseradish peroxidase (HRPO) (Jackson Immunochemicals) in blocking buffer A. The plates were washed as before and the substrate (100 gl/well) TMBlue (Universal Biologicals) was added. The plates were incubated for 10 min and colour development was stopped with 25 ~l/well 2 M-H2SO 4. A450 was measured with a multiwell spectrophotometer. Percentage specific inhibition of KK17 was calculated from (A ..... -Asamvle/Am~x) x 100 where Am~ x is the absorbance with no competing antibody and As~,nva e is the absorbance in the presence of a 1/200 monkey serum dilution. Twofold or greater specific inhibition above that obtained with preinfection sera was taken to be positive.
Peptide ELISA. Forty six overlapping peptides (20 mers)
representing the amino acid sequence of the external envelope glycoprotein of SIVm~ e 32H were obtained from Project EVA (reagent no. EVA 774) ( Table 2 ). The peptides were synthesized by Bachem. Three peptides were not available: peptide 5 (C 1 region amino acids 61 to 80), peptide 38 (V4 region amino acids 391 to 410) and peptide 46 (C4 region amino acids 471 to 490). The peptides were made up to 2 mg/ml according to the manufacturer's recommendations and stored in samples at -20 °C. Regions of the external envelope glycoprotein were named by analogy with HIV-1 gpl20 (Almond et al., 1992) .
Peptides were diluted to 2 ~g/ml in 0" 1 M-sodium bicarbonate buffer pH 9.6 and coated at 50 ~l/well in Falcon 3912 Microtest III PVC assay plates at 4 °C for 18 h. The plates were washed five times with PBST and residual reactive sites were blocked with 100 ~d/well PBST containing 1% (w/v) BSA and 10% (v/v) normal rabbit serum (blocking buffer B) for 1 h at 37 °C. The plates were washed as before and triplicate serum samples (50 ~tl/well) diluted to 1:200 with blocking buffer B were added. After 90 rain incubation at 37 °C the plates were washed as described above. Bound monkey antibodies were detected with rabbit anti-rhesus monkey IgG HRPO conjugate (Sigma) diluted to 1:1000 with blocking buffer B. The conjugate (50 ~l/well) was incubated in the plates for 30 min and the plates washed as before. Colour was developed with 50 ~l/well TMBlue for 15 min at room temperature and stopped with 50 ~l/well 2 M-H~SO 4. Plates were read for A450 and an average value was calculated for each sample.
Anti-gpl40 ELISA. Multiwell plates (Falcon 3912) were coated with recombinant SIV gpl40 (Repligen) at 2.5 ~tg/ml by overnight incubation at 37 °C. Reactive sites were blocked with blocking buffer A (see above) and serial dilutions of monkey sera in blocking buffer A were added. After 90 min incubation, wells were washed five times and bound antibody was detected by using rabbit anti-rhesus IgG-HRPO conjugate. Endpoint titres were calculated from titration curves using an A450 cut-off of 0'5.
Results
Responses in animals infected with uncloned or molecularly cloned SIVma ~ All animals infected with uncloned SIV .... produced antibodies that inhibited the binding of neutralizing monoclonal antibody KKI7 (Fig. 1) . The time course of development of the inhibitory response was variable. Most animals reached a plateau of inhibition and in two animals (85H and K8) the antibody level fell before death. Animal 54H was studied for 450 days after infection and showed a progressive rise in inhibitory antibody. This animal has remained clinically well for greater than 29 months but is persistently infected. Animal K8 made the lowest inhibitory responses and antibodies to the external glycoprotein were undetectable by Western blotting (data not shown). There was no obvious correlation between the dose of virus with which each animal was inoculated and the magnitude or speed of the KK17 inhibitory response.
In order for a direct comparison to be made between responses to linear and conformational epitopes, sera from animals infected with uncloned virus were tested when the response to the conformational epitope was at, or close to, maximum. Three linear antigenic sites were recognized (Fig. 2) addition 27H made a response to peptide 12 in the V1 region and this is the only animal to have been found to respond to this site (Fig. 2) . Macaque K8 sera reacted poorly with all peptides except for having low reactivity to peptide 49. Examination of pre-vaccination sera showed that there were very few non-specific reactions to the peptides used in this study: one of 16 sera showed reactivity to peptide 23, two of 16 to peptide 15 and one of 16 to peptide 9. All non-specific reactivities were below an A~50 of 0"5. As for the response to the conformational epitope no correlation could be seen between the concentration of virus inoculum and the level or specificity of antibodies to linear epitopes. Time-course studies were carried out on sera from 85H and 167 (data not shown) and indicated that the time of seroconversion to individual . ,,,,,,,,,,,, peptides was variable, even in individual animals. The analysis showed that I67 produced antibodies to the V3 peptide only late in infection, seroconverting to this peptide at 150 days and reaching a maximum response at 197 days post-challenge, but this response was weak and transient compared to those of other animals. In contrast I67 produced antibodies to the V1 and carboxy-terminal C5 peptides by 21 days post-infection and the titres reached higher maximal levels than that seen for the V3 peptide at 197 days post-challenge. At any time postchallenge 85H failed to respond to peptide 10 but seroconverted to the V3 and carboxy-terminal C5 peptide by 67 days post-infection. The time to seroconversion as measured by the conformational epitope response was similar to that seen for the earliest linear epitope responses for both I67 and 85H. Thus responses to the linear epitopes measured at or near the peak of the KK17 inhibition responses were taken to be typical. The maximum response, however, occurred at different times for linear and conformational epitopes. The time difference was small for 85H which had a maximum response to the conformational epitope 128 days postchallenge and at 106 days post-challenge to the V3 and C5 linear epitopes. In contrast I67 reached its maximum response to the conformational epitope at 67 days postchallenge but took 197 days to reach maximum response levels to both the V1 and C5 peptides.
All but two animals (57M and 43M) infected with the J5 molecular clone produced a response to the conformational epitope. A further animal (18L) that had been inoculated with a 10 -~ dilution of virus did not become infected and failed to make an antibody response. The maximum specific inhibition of KK17 binding measured in sera from J5-infected animals was between 17 and 40 % and was therefore generally lower than that seen in animals infected with uncloned virus (data not shown). Binding to peptides (Fig. 3) was measured 237 days after infection, a time corresponding to the maximum response to the conformational epitope. Both animals that failed to inhibit KK17 binding had reactivity to peptides in the V1, V3 and C5 regions. Rhesus 21M made only weak responses to both the conformational epitope and to linear epitopes. Sera from all other animals reacted to the V1, V3 and C5 peptides and four animals also had antibodies to the V2 region. Time-course analysis was done for animals 28L and 21M and this confirmed that the response measured at 237 days after infection was typical. As was seen for animals infected with the uncloned virus, the time taken to reach maximal response to individual peptides was variable; 28L produced a maximal response to peptide 30 at 75 days and to peptide 31 at 150 days. These maximal levels remained constant over the study period.
Overall, animals infected with molecularly cloned SIV .... produced a broader range of responses to external envelope peptides than did those infected with uncloned virus, with the C1, V2 and C2 regions being recognized in a proportion of animals in addition to V1, V3 and C5 ( Fig. 4a and b) .
Responses in SIV,~,e-vaccinated animals
On the day of virus challenge seven of eight animals receiving vaccine in saf-1 had antibodies that inhibited the binding of KK17 at or above twice the background level seen with sera taken pre-vaccination, whereas only half of the vaccinated animals given alum adjuvant inhibited KK17 binding at this level (Table 1) . In general responses were higher in animals given vaccine in the saf-1 adjuvant and this was reflected in the higher anti- body titres to recombinant gp140 seen in this group. A similar difference was seen also in the titre of antibodies to the p27 gag protein (data not shown). Little difference was seen between animals receiving a long or short vaccination schedule; however, only one animal receiving a low dose of vaccine in alum made a significant response to the conformational epitope. The eight animals vaccinated with inactivated SIV in alum produced only poor anti-peptide responses as expected. Sera from animals vaccinated with SIV in saf-1 adjuvant recognized a broad range of peptides (Fig. 4c ) similar to those recognized by sera from animals infected with molecularly cloned virus. Only half of the animals, however, recognized peptide 49 (C5 region) to which all SIVinfected animals reacted.
Discussion
An effective vaccine against HIV must elicit an immune response that will prevent the establishment of persistent infection in the host. The ability of passive immunization to prevent infection of cynomolgus monkeys by HIV-2 and SIV .... (Putkonen et al., 1991) indicates that antibodies directed to viral components are sufficient to prevent infection. Of particular interest are antibodies directed against the external envelope glycoprotein, gpl20, which is thought to be a key target for the immune response because of its external location on the virion and involvement in entry into host cells. In many membrane-bound viruses neutralization epitopes are conformationally determined. In HIV-1 the principal neutralization determinant (PND) is located within a disulphide cross-bridged loop in the third variable domain (V3) of gpl20 (Rusche et al., 1988) . Immunization with peptides containing the PND of HIV-1 is known to elicit strong neutralizing antibodies and, further, a substantial fraction of neutralizing antibodies in HIV-1 infected people can be removed by incubation with peptides containing the PND (Profy et al., 1990) . The PND of HIV-1 can therefore, at least in part, be mimicked with synthetic peptides. It is clear that the SIVma e V3 equivalent region (peptides 30 and 31) is highly immunogenic; all vaccinated and the majority of SIV-infected macaques responded to this region. However, this region of the external glycoprotein does not appear to be variable in SIV. For example, in one study, 27 clones obtained from two monkeys infected with SIgmaez39 were found to be conserved in the V3 equivalent region (Burns & Desrosiers, 1991) . Likewise the V3 equivalent region in clones derived from the SIVma e 32H used in this study was also found to be highly conserved (Almond et al., 1992) . A variable region has been described downstream of the V3 loop (Burns & Desrosiers, 1991) but this region was not recognized by sera in the present study. In addition, linear peptides corresponding to the V3 loop of the SIV envelope do not elicit neutralizing antibody (Javaherian et al., 1992) and monoclonal antibodies to this region have not been found to neutralize virus infectivity . Recently, Javaherian et al. (1992) have presented data suggesting that a neutralizing determinant of SIV .... is conformationally determined.
The majority of animals infected with uncloned SIV ..... made strong and sustained antibody responses that inhibited the binding of neutralizing monoclonal antibody KK17 that was directed to an unmapped conform-ational determinant of the SIV external envelope protein. This, in itself, does not prove that serum antibodies recognize an epitope identical to that reactive with the neutralizing monoclonal antibody since binding to neighbouring sites may interfere sterically; however, the data do suggest that the KK17 binding site may be highly immunogenic. One SIV-infected monkey (K8) that reacted only to the carboxy-terminal peptide of the external glycoprotein (peptide 49) also showed a weak transient response in the competition assay. This suggests that sequences in this region may be involved in the formation of the KK17 epitope. Part of this peptide may also fall in the transmembrane protein since two possible gpl60 cleavage sites are available (Chakrabarti et al., 1987) and, at least for HIV-1, both may be utilized (Fenouillet & Gluckman, 1992) . It is not clear why K8 failed to recognize other regions of the external glycoprotein, but seroconversion to the transmembrane protein in the absence of seroconversion to the external glycoprotein has been seen in several SIVm~o-infected animals (unpublished observation). The loss of antibody to a non-linear neutralizing epitope corresponding to progression to AIDS has been described in an SIVinfected macaque (Goudsmit et al., 1992) ; however, this was not a general finding in our study using the KK17 antibody. KK17 inhibition responses were generally lower or in two cases absent in animals infected with molecularly cloned virus; this was not due to an overall weaker response to the envelope glycoprotein in these animals since the reactivity of both uncloned and cloned SIV-infected animals to peptides was similar as was their antibody titre to recombinant gpl40 (data not shown).
In addition to the conformational determinant and the V3 region, two other regions defined by peptides (within the V1 and C5 regions) were identified as immunogenic in SIV-infected animals. The response seen to a linear epitope(s) within the V1 region in the majority of sera was similar to the response seen to the equivalent region of HIV-1 using sera from chimpanzees infected with HIV-1 (Stephens et al., 1992) . This predominant V1 response differs considerably from the results of Norrby et al. (1991) on studies of the linear antigenic sites in the envelope protein of HIV-2. The sequence of the peptide used in the present study starts amino-terminal to the equivalent peptide used by Norrby and in addition the length of peptides used in different studies can influence the results obtained (Goudsmit et al., 1988; Stephens et al., 1992; Mannervik et al., 1992) . The high degree of sequence variability seen in the V1 region of the 32H uncloned virus is consistent with this region being under immunological pressure (Almond et al., 1992) .
The strong reactivity of sera from infected animals to the carboxy-terminal region (peptide 49) is similar to the results of Mannervik et al. (1992) for B cell antigenic sites on HIV-2 gp125 and those of Norrby et al. (1991) for both HIV-1 and HIV-2. Palker et al. (1987) , using a synthetic peptide termed SP-22 which corresponded to the carboxy-terminal region of HIV-1, also found this region to be highly immunogenic. Antibodies to SP-22 could account for 70% of all anti-gpl20 antibodies, as determined by affinity chromatography, in human HIV-l-positive sera. These antibodies did not, however, neutralize HIV or inhibit HIV-induced syncytium formation in vitro. The amino acid sequence represented by peptide 49 is interesting as the equivalent region in HIV-1 has been reported to have sequence homology with the major ~ helices of HLA class I and class II molecules (Hounsell et al., 1992) . This region of the external glycoprotein is also involved in interaction with the transmembrane glycoprotein (Helseth et al., 1991) .
The V2 region is known to be immunogenic and to contain linear epitopes for virus-neutralizing antibody Benichou et al., 1992) . The uncloned SIV ..... 32H shows a high variability of amino acid sequence in this region (Almond et al., t992) and hence serum reactivity to V2 peptides may have been underestimated in animals infected with this virus pool. In contrast, the amino acid sequence of the V2 region peptides was identical to the sequence determined for the J5 molecular clone (DDBJ, EMBL and GenBank nucleotide sequence databases, accession no. D01065) and half of the animals infected with cloned virus had antibodies to this region.
Low frequency serum reactivity to constant region C1 was consistent with results from Norrby et al. (1991) who found that less than half of the sera studied from HIV-2-positive humans or monkeys were positive. None of the SIV-infected animals had antibodies to the putative CD4 binding region (peptides 42 and 43) and this may indicate that this region is sterically protected from antibody binding. This is in agreement with the lack of response to the CD4 binding region seen with human HIV-1 infections (Sun et al., 1989) .
In SIV ..... -vaccinated animals the results show that protection from virus challenge is not dependent upon the presence of antibodies to the conformational neutralizing determinant. It is now known that protection elicited with formalin-inactivated SIVma e grown in human cells involves, at least in part, antibodies to cellular proteins, possibly integrated into the virion envelope Le Grand et al., 1992; Cranage et al., 1993) . The saf-1 adjuvant was capable of eliciting higher antibody responses to both the conformational epitope and to the linear epitopes than those obtained with alum, which is in agreement with the results of Haigwood et al. (1992) . The lower reactivity to the conformational and C5 linear epitopes, compared to the responses to the V1 and V3 regions, suggests that these epitopes may be susceptible to the fixation process. The production of antibodies to the V2 region seen with immunized animals given saf-1 adjuvant is particularly encouraging since, in HIV-1, this region may be a target for cross-neutralizing antibodies (FunK et al., 1992) .
The elucidation of the linear and conformational antigenic sites on the external envelope glycoprotein of SIV ..... that are immunogenic in SIV-infected animals and are conserved following inactivation and presentation in a vaccine formulation has importance in the use of the SIV model for the design of future vaccines based on purified native viral components or on recombinant products.
